Triple

T21289787
Position Surface form Disambiguated ID Type / Status
Subject Paul Schimmel E524754 entity
Predicate coFounded P104 FINISHED
Object Cubist Pharmaceuticals NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Cubist Pharmaceuticals | Statement: [Paul Schimmel, coFounded, Cubist Pharmaceuticals]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Cubist Pharmaceuticals
Context triple: [Paul Schimmel, coFounded, Cubist Pharmaceuticals]
  • A. Portola Pharmaceuticals
    Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
  • B. Millennium Pharmaceuticals
    Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
  • C. Mapp Biopharmaceutical
    Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
  • D. Jazz Pharmaceuticals
    Jazz Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative medicines for sleep disorders, oncology, and rare diseases.
  • E. Cubic Corporation
    Cubic Corporation is a technology-driven defense and transportation solutions company known for providing fare collection systems, training, and mission support services to governments and transit agencies worldwide.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Cubist Pharmaceuticals
Target entity description: Cubist Pharmaceuticals was a biopharmaceutical company best known for developing and commercializing antibiotics to treat serious and drug-resistant infections.
  • A. Portola Pharmaceuticals
    Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
  • B. Millennium Pharmaceuticals
    Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
  • C. Mapp Biopharmaceutical
    Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
  • D. Jazz Pharmaceuticals
    Jazz Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative medicines for sleep disorders, oncology, and rare diseases.
  • E. Cubic Corporation
    Cubic Corporation is a technology-driven defense and transportation solutions company known for providing fare collection systems, training, and mission support services to governments and transit agencies worldwide.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b5171f6c8190a5d57201ede73811 completed April 16, 2026, 10:08 a.m.
NER Named-entity recognition batch_69e736d9467881908ec5b1dec76e6f5d completed April 21, 2026, 8:35 a.m.
Created at: April 16, 2026, 4:03 p.m.